Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 4
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
A new model to estimate duration of survival in patients with hepatocellular carcinoma with BCLC intermediate stage.
Ninomiya M, Tsuruoka M, Inoue J, Hiraoka A, Iwata T, Sano A, Sato K, Onuki M, Sawahashi S, Kuroda H, Oikawa T, Fujita M, Abe K, Katsumi T, Sato W, Igarashi G, Iino C, Endo T, Tanabe N, Numao H, Iijima K, Matsumoto T, Ohira H, Ueno Y, Masamune A. Ninomiya M, et al. Among authors: onuki m. Sci Rep. 2023 Nov 25;13(1):20739. doi: 10.1038/s41598-023-48068-7. Sci Rep. 2023. PMID: 38007597 Free PMC article.
Switching to Tenofovir Alafenamide Fumarate in Chronic Hepatitis B Patients Who Had Detectable HBV DNA during Treatment with Entecavir.
Sato K, Inoue J, Akahane T, Kobayashi T, Takai S, Nakamura T, Sato T, Kimura O, Ninomiya M, Iwata T, Sano A, Tsuruoka M, Onuki M, Sawahashi S, Niitsuma H, Masamune A. Sato K, et al. Among authors: onuki m. Tohoku J Exp Med. 2022 Nov 12;258(4):277-285. doi: 10.1620/tjem.2022.J084. Epub 2022 Oct 14. Tohoku J Exp Med. 2022. PMID: 36244758 Free article.
Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study.
Sato K, Inoue J, Akahane T, Kobayashi T, Sato S, Kisara N, Ninomiya M, Iwata T, Sano A, Tsuruoka M, Onuki M, Masamune A. Sato K, et al. Among authors: onuki m. Medicine (Baltimore). 2022 Sep 30;101(39):e30630. doi: 10.1097/MD.0000000000030630. Medicine (Baltimore). 2022. PMID: 36181074 Free PMC article. Clinical Trial.
Non-Achievement of Alanine Aminotransferase Normalization Associated with the Risk of Hepatocellular Carcinoma during Nucleos(t)ide Analogue Therapies: A Multicenter Retrospective Study.
Inoue J, Kobayashi T, Akahane T, Kimura O, Sato K, Ninomiya M, Iwata T, Takai S, Kisara N, Sato T, Nagasaki F, Miura M, Nakamura T, Umetsu T, Sano A, Tsuruoka M, Onuki M, Niitsuma H, Masamune A, Therme Study Group. Inoue J, et al. Among authors: onuki m. J Clin Med. 2022 Apr 22;11(9):2354. doi: 10.3390/jcm11092354. J Clin Med. 2022. PMID: 35566481 Free PMC article.
Usefulness of the Fibrosis-4 index and alanine aminotransferase at 1 year of nucleos(t)ide analog treatment for prediction of hepatocellular carcinoma in chronic hepatitis B patients.
Inoue J, Akahane T, Kobayashi T, Kimura O, Sato K, Ninomiya M, Iwata T, Takai S, Kisara N, Sato T, Nagasaki F, Miura M, Nakamura T, Umetsu T, Sano A, Tsuruoka M, Onuki M, Sawahashi S, Niitsuma H, Masamune A; THERME Study Group. Inoue J, et al. Among authors: onuki m. Hepatol Res. 2024 Feb;54(2):131-141. doi: 10.1111/hepr.13957. Epub 2023 Sep 6. Hepatol Res. 2024. PMID: 37621201